JP6556526B2 - Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate - Google Patents
Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate Download PDFInfo
- Publication number
- JP6556526B2 JP6556526B2 JP2015128874A JP2015128874A JP6556526B2 JP 6556526 B2 JP6556526 B2 JP 6556526B2 JP 2015128874 A JP2015128874 A JP 2015128874A JP 2015128874 A JP2015128874 A JP 2015128874A JP 6556526 B2 JP6556526 B2 JP 6556526B2
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- mosapride
- bovine
- acceptable salt
- prophylactic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000283690 Bos taurus Species 0.000 title claims description 47
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 title claims description 33
- 229960004085 mosapride Drugs 0.000 title claims description 33
- 208000010643 digestive system disease Diseases 0.000 title claims description 7
- 230000003449 preventive effect Effects 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title description 9
- 229940124597 therapeutic agent Drugs 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 210000004767 rumen Anatomy 0.000 claims description 16
- 230000000069 prophylactic effect Effects 0.000 claims description 13
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 238000006073 displacement reaction Methods 0.000 claims description 7
- 206010000060 Abdominal distension Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 208000024330 bloating Diseases 0.000 claims description 6
- 208000010444 Acidosis Diseases 0.000 claims description 5
- 208000004232 Enteritis Diseases 0.000 claims description 5
- 230000007950 acidosis Effects 0.000 claims description 5
- 208000026545 acidosis disease Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010061857 Fat necrosis Diseases 0.000 claims description 3
- 210000003165 abomasum Anatomy 0.000 claims description 3
- 210000002787 omasum Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 230000005176 gastrointestinal motility Effects 0.000 description 9
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 8
- 229960004503 metoclopramide Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- MIOUTPXNKVBIFR-UHFFFAOYSA-J dicalcium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Ca+2].[Ca+2].C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-] MIOUTPXNKVBIFR-UHFFFAOYSA-J 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- -1 magnesium aluminate Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KVKIQHMTGSGTFO-UHFFFAOYSA-N mosapride citrate dihydrate Chemical group O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O.CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 KVKIQHMTGSGTFO-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、ウシの消化器疾患の予防剤または治療剤に関する。より詳細には、4−アミノ−5−クロロ−2−エトキシ−N−[[4−(4−フルオロベンジル)−2−ホルモニル]メチル]ベンズアミド(以下、「モサプリド」ということもある)またはその生理学的に許容される塩を有効成分とする消化管運動機能促進作用による牛の消化器疾患の予防剤または治療剤に関する。 The present invention relates to a preventive or therapeutic agent for bovine digestive system diseases. More specifically, 4-amino-5-chloro-2-ethoxy-N-[[4- (4-fluorobenzyl) -2-formonyl] methyl] benzamide (hereinafter sometimes referred to as “mosapride”) or its The present invention relates to a preventive or therapeutic agent for digestive tract diseases of cattle due to a gastrointestinal motility function promoting action comprising a physiologically acceptable salt as an active ingredient.
ヒトに対してモサプリドクエン酸塩は、選択的セロトニン5−HT4受容体作動薬で、ドパミンD2受容体遮断作用を示さない消化管運動機能促進薬として知られている(特許文献1)。
モサプリドクエン酸塩を有効成分とする製剤は、慢性胃炎に伴う消化器症状の改善、経口腸管洗浄剤によるバリウム注腸X線造影検査前処置の補助を目的として既に実用化され、日本では「ガスモチン」なる商標名の下に市販されている。
For humans, mosapride citrate is a selective serotonin 5-HT 4 receptor agonist and is known as a gastrointestinal motility function promoter that does not show a dopamine D 2 receptor blocking action (Patent Document 1).
A preparation containing mosapride citrate as an active ingredient has already been put into practical use for the purpose of improving gastrointestinal symptoms associated with chronic gastritis and assisting in pretreatment of barium enema X-ray imaging with an oral intestinal irrigant. Is marketed under the trade name "".
獣医学領域でもモサプリドクエン酸塩は、イヌの上部消化管運動機能改善薬として既に市販され、またウマの便秘疝における消化管運動機能低下の改善を効能・効果とし製造販売承認申請がなされている。 In the veterinary field, mosapride citrate has already been marketed as a drug for improving upper gastrointestinal motility in dogs, and an application for marketing approval has been filed for the improvement and reduction of gastrointestinal motility in equine constipation. .
一方、モサプリドクエン酸塩のウシの消化管運動機能改善への適用は、ウシの特殊で複雑な胃の構造から、これまで報告がなく、困難と考えられてきた。 On the other hand, the application of mosapride citrate to the improvement of gastrointestinal motility in cattle has not been reported so far and has been considered difficult because of the special and complicated structure of the stomach in cattle.
ウシの胃はヒトや他の哺乳動物の胃と異なり、1つの胃でなく、第1胃から第4胃までの4つの胃が存在し、その内ヒトやイヌなどの哺乳動物でいわゆる「胃」と呼ばれる胃酸を分泌し、タンパク質を分解する機能を有する器官は、第4胃だけであり、第1胃〜第3胃にはそのような機能を有してないことが知られている。そして、その4つの胃の中で、ウシの独特の消化機構を担っているのが第1胃である。第1胃は非常に大きく、肉牛で〜200リットル、乳牛では〜300リットルの容積があり、ドラム缶の180リットルを凌ぐ大きさがあり、通常の哺乳動物では消化できない草に含まれるセルロースなどの食物繊維を、第1胃に存在する膨大な数の微生物の助けにより、発酵させ消化吸収しやすくさせ、消化された栄養分を吸収するはたらきを有している。
そして、ウシはいったん咀嚼、嚥下した胃内容物を口腔内に送り戻し、再び咀嚼、嚥下する、いわゆる「反芻」という独特の消化機構も有しており、これら複雑な消化管のメカニズムのため、通常の哺乳動物に適用される消化管運動機能改善目的の薬剤は、無効または限定的な効果と考えられてきた。
Unlike the stomachs of humans and other mammals, the bovine stomach has four stomachs from the first stomach to the fourth stomach instead of one stomach. Among them, mammals such as humans and dogs have so-called “stomach”. It is known that the only organ that has the function of secreting gastric acid and degrading protein called “the stomach 4”, and the first to third stomachs do not have such a function. Among the four stomachs, the rumen is responsible for the unique digestive mechanism of cattle. The rumen is very large, has a volume of ~ 200 liters for beef cattle, ~ 300 liters for dairy cows, and has a size exceeding 180 liters for drums, and foods such as cellulose contained in grass that cannot be digested by normal mammals. The fiber has the function of facilitating fermentation and digestion absorption with the help of a huge number of microorganisms present in the rumen, and absorbing digested nutrients.
And cows also have a unique digestion mechanism called so-called “rumination” that sends the gastric contents once chewed and swallowed back into the oral cavity, and chews and swallows again. Because of these complicated mechanisms of the digestive tract, Drugs intended to improve gastrointestinal motility function applied to normal mammals have been considered ineffective or limited effects.
家畜のウシが罹患する疾患のうち、胃腸が原因と考えられる消化器疾患の発生率は全体の10%程度と考えられているが、その治療には主にメトクロプラミドが使用されてきている。メトクロプラミドの薬理作用はドパミンD2受容体拮抗作用とセロトニン5−HT4受容体刺激作用を併せ持ち、ウシで第一胃食滞、鼓脹症、単純性消化不良などの効能効果が承認され、動物用医薬品として広く用いられている。 Of the diseases affecting domestic cattle, the incidence of gastrointestinal diseases thought to be caused by gastrointestinal tract is considered to be about 10% of the total, but metoclopramide has been mainly used for the treatment. Metoclopramide has a pharmacological action of both dopamine D 2 receptor antagonism and serotonin 5-HT 4 receptor stimulation, and has been approved for use in animals, such as rumen stagnation, bloating and simple dyspepsia. Widely used as a medicine.
しかしながら、ウシの消化器疾患に対して、臨床現場では多くの場合メトクロプラミドが使用されてはいるが、その効果については疑問も多く、必ずしも明確でないとの意見も多い。また、メトクロプラミドはウシの消化管運動機能促進作用がほとんどないとの報告も出されているなど(非特許文献1参照)、その効果については十分ではないところもあることから、ウシにおける消化器疾患の効果的で実用的な新たな治療剤が畜産の獣医学領域で切望されていた。 However, although metoclopramide is often used in clinical settings for digestive diseases of cattle, there are many doubts about the effect and many opinions are not necessarily clear. In addition, it has been reported that metoclopramide has almost no action to promote gastrointestinal motility in cattle (see Non-Patent Document 1). An effective and practical new therapeutic agent was eagerly desired in the veterinary field of animal husbandry.
本発明の目的は、ウシの消化器疾患の効果的で実用的な予防剤および治療剤を提供する事である。 An object of the present invention is to provide an effective and practical preventive and therapeutic agent for bovine digestive tract diseases.
本発明者らは、メトクロプラミドに代わる新たなウシの消化器疾患治療薬として鋭意研究を重ねた中で、これまでウシの複雑な胃の構造からウシへの適用の報告がなかった薬剤ではあるが、メトクロプラミドとは作用メカニズムが異なり、ドパミンD2受容体遮断作用を示さない選択的セロトニン5−HT4受容体作動薬で、消化管運動機能促進作用のあるモサプリドクエン酸塩に着目した。モサプリドクエン酸塩の主作用であるセロトニン5−HT4受容体作動については、非特許文献1で反芻動物であるウシへのセロトニン5−HT4受容体作動機構での消化運動促進効果は非常に低いという見解が示されていたが、そのような知見にもかかわらず、実際モサプリドクエン酸塩を消化器疾患のあるウシに適用したところ、ウシにおける種々の消化器疾患に対し、これまでにない顕著な効果を示すことを見出し、また第1胃に対しても強い収縮作用を有することを見出し、本発明を完成するに至った。 While the present inventors have intensively studied as a new bovine digestive tract disease treatment to replace metoclopramide, it has not been reported to be applied to cattle due to the complicated structure of the bovine stomach. The mesoclopramide is a selective serotonin 5-HT 4 receptor agonist that has a different mechanism of action and does not show a dopamine D 2 receptor blocking action, and focused on mosapride citrate, which has a gastrointestinal motor function promoting action. Regarding serotonin 5-HT 4 receptor operation, which is the main action of mosapride citrate, the non-patent document 1 shows that the effect of promoting the digestive motility in the serotonin 5-HT 4 receptor operation mechanism on the ruminant bovine is very In spite of such findings, mosapride citrate was actually applied to cattle with digestive illnesses, but never before for various digestive illnesses in cattle. It has been found that a remarkable effect is exhibited, and also has a strong contracting action on the rumen, and the present invention has been completed.
すなわち、本発明は、以下のものに関する。 That is, the present invention relates to the following.
<1>モサプリドまたは生理学的に許容される塩を含む、ウシの消化器疾患の治療および/または予防剤。 <1> A therapeutic and / or preventive agent for bovine gastrointestinal diseases, comprising mosapride or a physiologically acceptable salt.
<2>ウシの消化器疾患が第一胃食滞、鼓脹症、ルーメンアシドーシス、急性第一胃拡張、第三胃食滞、第四胃変位・捻転、脂肪壊死症、および/または胃炎・腸炎等による食欲不振である、<1>の治療および/または予防剤。 <2> Bovine gastrointestinal disorders are rumen stasis, bloating, rumen acidosis, acute ruminal dilatation, stagnation of the stomach, ruminal displacement / torsion, liponecrosis, and / or gastritis / enteritis The therapeutic and / or prophylactic agent of <1>, which is anorexia due to, and the like.
<3>モサプリドまたは生理学的に許容される塩がモサプリドクエン酸塩である、<1>または<2>の治療および/または予防剤。 <3> The therapeutic and / or prophylactic agent of <1> or <2>, wherein the mosapride or physiologically acceptable salt is mosapride citrate.
<4>経口剤である<1>〜<3>のいずれかの治療および/または予防剤。 <4> The therapeutic and / or prophylactic agent according to any one of <1> to <3>, which is an oral preparation.
<5>注射剤である<1>〜<3>のいずれかの治療および/または予防剤。 <5> The therapeutic and / or prophylactic agent according to any one of <1> to <3>, which is an injection.
<6>1日あたり0.01〜100mg/kgで投与されることを特徴とする<4>の治療および/または予防剤。 <6> The therapeutic and / or prophylactic agent according to <4>, which is administered at 0.01 to 100 mg / kg per day.
<7>1日あたり0.01〜100mg/kgで投与されることを特徴とする<5>の治療および/または予防剤。 <7> The therapeutic and / or prophylactic agent according to <5>, which is administered at 0.01 to 100 mg / kg per day.
<8>治療上の有効量のモサプリドまたは生理学的に許容される塩をウシに投与することを特徴とする、ウシの消化器疾患の治療および/または予防方法。 <8> A method for treating and / or preventing bovine gastrointestinal diseases, comprising administering a therapeutically effective amount of mosapride or a physiologically acceptable salt to a bovine.
<9>ウシの消化器疾患が第一胃食滞、鼓脹症、ルーメンアシドーシス、急性第一胃拡張、第三胃食滞、第四胃変位・捻転、脂肪壊死症、および/または胃炎・腸炎等による食欲不振である、<8>の治療および/または予防方法。 <9> Bovine gastrointestinal disorders are rumen stasis, bloating, rumen acidosis, acute ruminal dilatation, stagnation of the stomach, ruminal displacement / torsion, steatosis, and / or gastritis / enteritis <8> A method for the treatment and / or prevention of anorexia due to, and the like.
<10>ウシの消化器疾患の治療および/または予防に用いられる、モサプリドまたは生理学的に許容される塩を含む組成物。 <10> A composition comprising mosapride or a physiologically acceptable salt for use in the treatment and / or prevention of digestive tract diseases in cattle.
<11>ウシの消化器疾患の治療および/または予防剤を製造するための、モサプリドまたは生理学的に許容される塩の使用。 <11> Use of mosapride or a physiologically acceptable salt for producing a therapeutic and / or preventive agent for bovine digestive diseases.
本発明によれば、モサプリドクエン酸塩はウシの消化器疾患の予防および治療に対して極めて有用である。
また、メトクロプラミドで効果が認められない症例においても、治療効果が期待できるため、これまで手術で治療していた症例や回復の見込みがなく廃棄されていた症例についても治療が可能となるため経済的な損失を大きく抑えることができる。
更に本発明では、ウシの複雑な胃の構造にもかかわらず、経口投与によってもその効果が得られることから、非経口剤のような製造における無菌的な処理や、投与時の無菌的取扱いを不要とすることができる。
According to the present invention, mosapride citrate is very useful for the prevention and treatment of digestive diseases in cattle.
In addition, since the therapeutic effect can be expected even in cases where metoclopramide is not effective, it is economical because it can be treated even in cases that have been treated by surgery or cases that have been discarded without expectation of recovery. Loss can be greatly reduced.
Furthermore, in the present invention, since the effect can be obtained even by oral administration despite the complicated stomach structure of bovine, aseptic treatment in the manufacture of parenteral agents and aseptic handling at the time of administration are possible. It can be unnecessary.
以下に、本願明細書において記載する用語等の意義、本発明の実施の形態等を示して、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail with reference to the meanings of terms and the like described in the present specification and the embodiments of the present invention.
モサプリドの生理学的に許容される塩としては、好ましくは酸付加塩がよい。たとえば有機酸の付加塩としては、ギ酸塩、酢酸塩、乳酸塩、アジピン酸塩、クエン酸塩、酒石酸塩、フマル酸塩、メタンスルホン酸塩、マレイン酸塩等が挙げられ、無機酸の付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等が例示できる。この中でも特にクエン酸塩が好ましい。さらに、モサプリドまたはその生理学的に許容される塩は、溶媒和物であってもよく、水和物および非水和物であってもよい。好ましくはクエン酸塩の水和物がよく、とりわけクエン酸塩・2水和物が好ましい。 The physiologically acceptable salt of mosapride is preferably an acid addition salt. For example, organic acid addition salts include formate, acetate, lactate, adipate, citrate, tartrate, fumarate, methanesulfonate, maleate, etc. Examples of the salt include hydrochloride, sulfate, nitrate, phosphate and the like. Of these, citrate is particularly preferable. Furthermore, mosapride or a physiologically acceptable salt thereof may be a solvate, a hydrate and a non-hydrate. Citrate hydrate is preferred, and citrate dihydrate is particularly preferred.
本明細書において使用する「ウシの消化器疾患」とは、第一胃食滞、鼓脹症、ルーメンアシドーシス、急性第一胃拡張、第三胃食滞、第四胃変位・捻転、脂肪壊死症、胃炎・腸炎等による食欲不振等が含まれる。 As used herein, “bovine gastrointestinal disease” refers to ruminal stagnation, bloating, rumen acidosis, acute ruminal dilatation, stagnation of the stomach, displacement and torsion of the stomach, and fatty necrosis And anorexia due to gastritis and enteritis.
本発明で用いるモサプリドまたは医薬的に許容される塩の用量(治療上の有効量)は、その治療効果等が得られれば特に制限はないが、経口投与であれば、1日あたり0.01〜100mg/kgで用いられ、好ましくは、0.05〜50mg/kg、より好ましくは0.05〜25mg/kgで用いられる。また、注射剤であれば、1日あたり0.01〜100mg/kgで用いられ、好ましくは、0.01〜50mg/kg、より好ましくは0.01〜25mg/kgで用いられる。また、1日1〜4回、好ましくは1〜3回に分けて投与してもよい。 The dose (therapeutically effective amount) of mosapride or pharmaceutically acceptable salt used in the present invention is not particularly limited as long as the therapeutic effect is obtained, but 0.01 mg per day for oral administration. It is used at -100 mg / kg, preferably 0.05-50 mg / kg, more preferably 0.05-25 mg / kg. Moreover, if it is an injection, it is used at 0.01-100 mg / kg per day, Preferably it is 0.01-50 mg / kg, More preferably, it is used at 0.01-25 mg / kg. Moreover, it may be administered 1 to 4 times a day, preferably 1 to 3 times.
本発明の投与形態としては、経口剤、注射剤のいずれでもよく、経口剤であれば錠剤、カプセル剤、散剤、顆粒剤、液剤、懸濁剤、シロップ剤などが挙げられる。経口剤としてはウシに強制的に飲ませてもよく、また餌と共に摂取させてもよい。注射剤であれば、静脈内、皮下、筋肉内投与が可能である。
また、本発明の組成物は、本発明化合物またはその塩の有効量を、製剤学的に許容される担体と共に含有する一般的な医薬製剤形態に調製されている。
The dosage form of the present invention may be either an oral preparation or an injection. Examples of oral dosage forms include tablets, capsules, powders, granules, solutions, suspensions, and syrups. As an oral preparation, it may be forcibly fed to cattle or taken with food. Injectables can be administered intravenously, subcutaneously, or intramuscularly.
The composition of the present invention is prepared in a general pharmaceutical preparation form containing an effective amount of the compound of the present invention or a salt thereof together with a pharmaceutically acceptable carrier.
経口剤としては、薬学的に許容される賦形剤、添加剤とともに製剤化される。薬学的に許容される賦形剤、添加剤としては、担体、結合剤、香料、緩衝剤、増粘剤、着色剤、安定剤、乳化剤、分散剤、懸濁化剤、防腐剤等が挙げられる。具体的には、本発明化合物を乳糖、マンニトール、ブドウ糖、ヒドロキシプロピルセルロース、微結晶セルロース、デンプン、ポリビニルピロリドン、メタケイ酸、アルミン酸マグネシウムなどと混合し、混合物を常法に従って賦型することにより実施できる。該混合物には、更に適当な添加剤、例えばステアリン酸マグネシウムのような滑沢剤;繊維素グルコール酸カルシウムのような崩壊剤;ラクトースのような安定化剤;グルタミン酸、アスパラギン酸のような溶解補助剤などを配合することができる。また甘味剤、風味剤、芳香剤、防腐剤などを添加配合することもできる。
カプセルは、本発明に係る化合物を薬学的に許容される担体と共に中に入れることにより製剤できる。本発明に係る化合物は薬学的に許容される賦形剤と共に混合し、または賦形剤なしにカプセルの中に入れることができる。
経口投与に適切な液剤、懸濁剤等は、本発明化合物を水に加え、着色剤、香料、安定化剤、甘味剤、溶解剤、増粘剤等を必要に応じて加え製造することができる。また経口投与に適切な液剤、懸濁剤等は、本発明化合物を分散剤とともに水に加え、粘稠にすることによっても製造できる。増粘剤としては、例えば、薬学的に許容される天然または合成ガム、レジン、メチルセルロース、ナトリウムカルボキシメチルセルロースまたは公知の懸濁化剤等が挙げられる。
散剤は、薬学的に許容される散剤の基剤と共に製剤化される。基剤としては、タルク、ラクトース、澱粉等が挙げられる。
Oral preparations are formulated with pharmaceutically acceptable excipients and additives. Examples of pharmaceutically acceptable excipients and additives include carriers, binders, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, and the like. It is done. Specifically, the compound of the present invention is mixed with lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, metasilicic acid, magnesium aluminate and the like, and the mixture is shaped according to a conventional method. it can. The mixture further includes suitable additives such as lubricants such as magnesium stearate; disintegrants such as calcium calcium glycolate; stabilizers such as lactose; solubilizing aids such as glutamic acid and aspartic acid. An agent or the like can be blended. Sweetening agents, flavoring agents, fragrances, preservatives and the like can also be added and blended.
Capsules can be formulated by placing a compound according to the invention in a pharmaceutically acceptable carrier. The compounds according to the invention can be mixed with pharmaceutically acceptable excipients or placed in capsules without excipients.
Solutions, suspensions and the like suitable for oral administration can be produced by adding the compound of the present invention to water and adding a colorant, a fragrance, a stabilizer, a sweetener, a solubilizer, a thickener and the like as necessary. it can. Solutions, suspensions and the like suitable for oral administration can also be produced by adding the compound of the present invention together with a dispersant to water to make it viscous. Examples of the thickener include pharmaceutically acceptable natural or synthetic gum, resin, methylcellulose, sodium carboxymethylcellulose, or a known suspending agent.
Powders are formulated with a pharmaceutically acceptable powder base. Examples of the base include talc, lactose, starch and the like.
注射剤には、無菌の水性または非水性の溶液剤、懸濁剤、乳濁剤などが含まれる。水性の注射剤は、例えば注射用蒸留水及び生理食塩水を希釈剤として利用して常法に従い調製することができる。非水性の注射剤は、例えばプロピレングリコール、ポリエチレングリコール、オリーブ油のような植物油;エタノールなどのアルコール類;ポリソルベート80などを希釈剤乃至担体として利用して常法に従い調製できる。これらの注射剤には、更に防腐剤、湿潤剤、乳化剤、分散剤、安定化剤(例えばラクトース)、溶解補助剤(例えば、グルタミン酸、アスパラギン酸)のような補助剤を添加配合することができる。調製される注射剤は、常法に従って、例えばバクテリア保留フィルターを通す濾過、殺菌剤の配合またはガンマ線などの放射線照射によって無菌化される。また、注射剤は、無菌の固形剤を製造後、無菌水または無菌の注射用溶媒に溶解して実用される、用時溶解剤形態に調製することもできる。 Injections include sterile aqueous or non-aqueous solutions, suspensions, emulsions and the like. An aqueous injection can be prepared according to a conventional method using, for example, distilled water for injection and physiological saline as diluents. Non-aqueous injections can be prepared according to conventional methods using, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil; alcohols such as ethanol; polysorbate 80 and the like as diluents or carriers. These injections may further contain additives such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (for example, lactose) and solubilizing agents (for example, glutamic acid and aspartic acid). . The prepared injection is sterilized according to a conventional method, for example, filtration through a bacteria-retaining filter, blending of a bactericidal agent, or irradiation with radiation such as gamma rays. In addition, the injection can be prepared in a form of a dissolution solution at the time of use, which is practically used by dissolving a sterile solid preparation in sterile water or a sterile solvent for injection after production.
以下に、本発明の有利な効果を示すため、実施例を示すが、これらは例示的なものであって、本発明はいかなる場合にも、以下の具体例に制限されるものではない。当業者は、以下に示す実施例に記載の条件を適宜変更して本発明を実施することができ、かかる変更は本願特許請求の範囲に包含される。 In order to show the advantageous effects of the present invention, examples will be shown below. However, these examples are illustrative, and the present invention is not limited to the following specific examples in any case. Those skilled in the art can implement the present invention by appropriately changing the conditions described in the following examples, and such changes are included in the scope of the claims of the present application.
実施例1.脂肪壊死症のウシに対し、モサプリドクエン酸塩を投与した症例
メトクロプラミドを投与しても症状の改善がみられなかった、脂肪壊死症のウシ3症例に、モサプリドクエン酸塩を1mg/kg、1日2回、投与した結果、投与翌日に排便および食欲の改善が認められた(表1)。
Example 1. Cases where mosapride citrate was administered to cattle with liponecrosis. Three measles cattle with fat necrosis that did not improve after administration of metoclopramide were treated with 1 mg / kg of mosapride citrate. As a result of administration twice a day, defecation and appetite improvement were observed on the day after administration (Table 1).
実施例2.第四胃左方変位のウシに対し、モサプリドクエン酸塩を投与した症例
パンテチン製剤を投与しても症状の改善がみられなかった、第四胃左方変位のウシ3症例に、ローリング処置後にモサプリドクエン酸塩を1mg/kg、1日2回、投与した結果、投与翌日に排便し、手術することなく完治した(表2)。
Example 2 Cases where mosapride citrate was administered to bovines with left displacement of the left stomach As a result of administration of mosapride citrate at 1 mg / kg twice a day, the stool was excreted the day after administration, and the patient was completely cured without surgery (Table 2).
実施例3.十二指腸捻転および食滞のウシに対し、モサプリドクエン酸塩を投与した症例
十二指腸捻転のウシに整復術後、モサプリドクエン酸塩を1mg/kg、1日2回、投与した結果、廃用予定が術後1週間で回復した(表3,No. 1)。
食滞のウシに対し、モサプリドクエン酸塩を1mg/kg、1日2回、投与した結果、投与翌日に排便および食欲の改善が認められた(表3,No. 2)。
Example 3 Cases where mosapride citrate was administered to cattle with duodenal torsion and stagnation. After reduction, mosapride citrate was administered at a dose of 1 mg / kg twice a day. It recovered in one week later (Table 3, No. 1).
As a result of administration of mosapride citrate 1 mg / kg twice a day to stagnant cattle, defecation and appetite were improved the day after administration (Table 3, No. 2).
これまでウシの第一胃食滞や第四胃変位などの消化器疾患において消化管運動機能促進作用があるとされるメトクロプラミドやパンテチンを投与しても治療効果か認められない症例に対しても、モサプリドクエン酸塩をウシに使用することにより治療効果が期待できることから、ウシの消化管運動機能促進剤として応用範囲は広く、畜産分野において多大に貢献できることが期待できる。 For patients who have been treated with metoclopramide or pantethine, which is considered to have a gastrointestinal motility function promoting action in gastrointestinal diseases such as rumen stagnation and rumen displacement in cattle Since the therapeutic effect can be expected by using mosapride citrate in cattle, it can be expected to contribute greatly in the field of livestock production because it has a wide range of applications as a bovine gastrointestinal motility promoter.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015128874A JP6556526B2 (en) | 2015-06-26 | 2015-06-26 | Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015128874A JP6556526B2 (en) | 2015-06-26 | 2015-06-26 | Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017014113A JP2017014113A (en) | 2017-01-19 |
JP6556526B2 true JP6556526B2 (en) | 2019-08-07 |
Family
ID=57827879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015128874A Active JP6556526B2 (en) | 2015-06-26 | 2015-06-26 | Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6556526B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114560822B (en) * | 2020-11-27 | 2024-05-28 | 鲁南制药集团股份有限公司 | Mosapride dicarboxylic acid crystal |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63264467A (en) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | Benzamide derivative |
JP2586542B2 (en) * | 1988-01-25 | 1997-03-05 | 藤沢薬品工業株式会社 | A therapeutic agent for cattle abomasum displacement |
-
2015
- 2015-06-26 JP JP2015128874A patent/JP6556526B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017014113A (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6448001B2 (en) | Liquid formulation | |
JP6336592B2 (en) | Pharmaceutical composition for treating pruritus conditions mediated through histamine H4 receptor | |
Fisher | Standards of care in the 21st century: the rabbit | |
JP2024508737A (en) | Methods and pharmaceutical compositions for treating diseases | |
CN104666401A (en) | Veterinary Chinese and western medicinal compound orally-disintegrating micropowder tablet and preparation method thereof | |
JP2005515213A (en) | A drinkable formulation comprising ketoprofen and its use in the simultaneous treatment of a group of animals for fever, inflammation and / or painful symptoms | |
JP6556526B2 (en) | Preventive or therapeutic agent for bovine digestive diseases in mosapride citrate | |
CN1222291C (en) | Novel uses of combined 5-HT 1A agonists and serotonin reuptake inhibitor | |
RU2725112C2 (en) | Methods of using phenoxypropylamine compounds for treating depression | |
US7074834B2 (en) | Long acting, reversible veterinary sedative and analgesic and method of use | |
Borisenko et al. | The efficacy tests results of the veterinary drug" trifuzol 1% solution for injection" | |
English et al. | Renal cortical hypoplasia in a dog | |
Fekry et al. | Assessment of a multimodal analgesia protocol in goats undergoing claw amputation | |
JP2586542B2 (en) | A therapeutic agent for cattle abomasum displacement | |
Jothi et al. | Evaluation of Collagen, Calcium Alginate Protectants on Healing of External Wound on Teat in Cows | |
KR102087415B1 (en) | Composition for large intestine administration comprising mosapride or pharmaceutical acceptable salts thereof as an effective component | |
RU2417782C1 (en) | Method of treating paunch acidosis | |
RU2283648C2 (en) | New application of combined selective antagonists of dopamine d2 receptor and agonists of 5-нт 1a receptor | |
Cassutto | Using drug therapy to treat priapism in two dogs | |
RU2007129408A (en) | METHOD OF GROWING PIGS IN THE PERIOD OF FEEDING | |
KR20220041862A (en) | Veterinary composition for prevention and/or treatment of cryptosporidiosis | |
US9284281B2 (en) | Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain | |
Hema Sayee et al. | Intussusception in a Jersey crossbred pregnant heifer | |
CN104398507B (en) | Benzazole compounds application in the medicine of preparation treatment chronic gastritis | |
KR20220038232A (en) | Composition for prevention or treatment of rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180406 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190702 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6556526 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |